Pediatric Cancer Dataset Gaps, FDA ‘High Bar’ Make Use Of External Control Arms Difficult

 
• By Sue Sutter

European data privacy regulations could further complicate efforts to build external control arms using real-world data that are housed outside the US, experts said at advisory committee meeting on use of real-world evidence in pediatric cancer drug development.

Boy with teddy bear
For pediatric cancer drug sponsors, it may be difficult to find a comparator arm outside their study. • Source: Alamy

More from Real-World Evidence

More from Clinical Trials